After settling a long dispute with its marketing partner for the US market, Orexigen Therapeutics has inked an agreement with Kwang Dong Pharm to distribute its obesity drug in South Korea, where demand is growing amid an increasing number of hypertension, hyperlipidemia and diabetes patients.
SEOUL - Orexigen Therapeutics Inc. has partnered with Kwang Dong Pharmaceutical Co. Ltd. to distribute its obesity drug Contrave (naltrexone/bupropion) in South Korea as it seeks to expand the drug’s global presence following the recent settlement of a dispute with its partner for the US market.
Under the terms of the agreement, the South Korean pharma firm will be responsible for seeking regulatory approval and for...
Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.
Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.
